Novartis drug candidate scores interim win in rare kidney disease trial
Chinook Therapeutics, Inc., a biotechnology company focused on developing precision medicines for kidney diseases, today announced it has entered into a license agreement with AbbVie, a research-based global biopharmaceutical company, for worldwide, exclusive rights to atrasentan, an endothelin receptor antagonist. Chinook will assume all development and commercialization responsibilities for atrasentan globally. Chinook plans to initiate a clinical trial of atrasentan in the second half of 2020 for biomarker-selected patients with a rare primary glomerular kidney disease at high risk for progressive kidney function loss.